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Sorafenib in Platinum-Treated Patients with Extensive Stage
Small Cell Lung Cancer
A Southwest Oncology Group (SWOG 0435) Phase II Trial
Barbara J. Gitlitz, MD,* James Moon, MS,† Bonnie S. Glisson, MD,‡
H. Joachim Reimers, MD, PhD,§ Martin J. Bury, MD, Justin D. Floyd, DO,¶
Thomas K. Schulz, MD,# P. Kothai Sundaram, MD,** Christopher Ho, MD,*
and David R. Gandara, MD††
Introduction: Sorafenib is a multikinase inhibitor affecting path-
ways involved in tumor progression and angiogenesis. We con-
ducted a phase II trial of sorafenib in platinum-treated patients with
extensive stage small cell lung cancer to determine the tumor
response rate, toxicity, and overall survival.
Methods: Patients with histologically confirmed, measurable dis-
ease, Zubrod performance status 0 to 1, and no more than 1 prior
platinum-based treatment were eligible. Patients were stratified
by platinum-sensitivity status: sensitive (progression 90 days after
platinum) or refractory (progression during or 90 days after
platinum). Patients were treated with sorafenib 400 mg orally twice
a day continuously on a 28-day cycle.
Results: Of 89 patients registered, 82 were evaluable for toxicity
assessment, and 83 were evaluable for response. There were four
partial responses seen among the 38 patients in the platinum-
sensitive stratum, for an estimated response rate of 11% (95%
confidence interval: 3–25%), and one partial response among the 45
patients in the platinum-refractory stratum, for an estimated re-
sponse rate of 2% (95% confidence interval: 0–12%). The median
overall survival estimates were 6.7 months (95% confidence inter-
val: 6.1–9.1 months) for the platinum-sensitive stratum and 5.3
months (95% confidence interval: 3.3–7.5 months) in the platinum-
refractory stratum. Nineteen patients discontinued treatment because
of adverse events or side effects from therapy.
Conclusions: Based on the lack of disease control seen in our trial,
further investigation of single-agent sorafenib in the small cell lung
cancer population is not recommended. Combination trials of sor-
afenib and chemotherapy are ongoing.
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Lung cancer was diagnosed in approximately 186,525Americans in 2009 and accounted for 159,390 cancer
deaths.1 The lifetime risk of developing lung cancer is 1:13
for men and 1:16 for women. Approximately 15% of these
cases will be diagnosed with small cell lung cancer (SCLC),
an aggressive malignancy that is usually extensive in two
thirds of patients at initial presentation. Patients with extensive
stage SCLC (ES-SCLC) are typically treated with platinum-
based chemotherapy regimens resulting in high response rates,
translating into improved survival and disease palliation. How-
ever, despite this initial chemosensitivity of treatment-naive
disease, the majority of patients experience a recurrence of
disease, which is usually drug resistant and lethal.
The activity of new chemotherapeutic agents in previ-
ously treated, relapsed SCLC can be distinguished based on
the response status to prior platinum-based chemotherapy.
Three categories of patients have been described: sensitive,
resistant, and refractory. Sensitive refers to patients who had
a first-line response that lasted 90 days after treatment was
completed. Refractory refers to patients who never responded
to first-line therapy or those whose cancer progressed during
first-line therapy. Resistant refers to patients who responded
initially but experienced a recurrence within 90 days of
completion of their primary therapy. Resistant patients are
often grouped together with refractory patients because of
their uniformly poor treatment outcomes, with infrequent
objective responses and dismal survival. Indeed, clinical trials
of salvage chemotherapy for relapsed SCLC often exclude
refractory/resistant patients.2 However, a phase III study
conducted at the Royal Marsden Hospital compared oral
topotecan with best supportive care for relapsed SCLC. Even
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in this population of patients “not considered as candidates
for standard intravenous therapy,” there was a statistically
significant survival benefit to treatment with topotecan (13.9
weeks versus 25.9 weeks).3 Statistical significance for sur-
vival was maintained in a subgroup of patients with a short
treatment-free interval 60 days, with median survival of
13.2 weeks versus 23.3 weeks.
Although topotecan offers advantage over best support-
ive care, improving outcomes in SCLC is certainly an area of
great therapeutic need. Therefore, platinum-treated patients
with relapsed SCLC are a potentially unique group to target
and differentiate along sensitivity status when studying
agents with unique mechanisms of action.
Sorafenib (BAY 43-9006) is an orally bioavailable,
small molecule inhibitor of multiple intracellular and receptor
protein kinases involved in signaling pathways that control
tumor growth, stromal environment, and angiogenesis. Specifi-
cally, sorafenib is a potent inhibitor of wild type and mutant
B-raf, vascular endothelial growth factor receptor (VEGFR)-1,
VEGFR-2, VEGFR-3, platelet derived growth factor receptor
(PDGFR)-, c-KIT, Flt3, and RET.
Current evidence suggests that angiogenesis plays an
important role in SCLC growth and regulation.4,5 On the basis
of the potential role of inhibition of angiogenic pathways
combined with blockade of cell growth pathways, we con-
ducted a phase II trial of sorafenib in relapsed/refractory
SCLC (Southwest Oncology Group 0435).
PATIENTS AND METHODS
The objectives of the study were to evaluate the effi-
cacy of sorafenib in previously treated, platinum-sensitive
and platinum-refractory patients with ES-SCLC. Our primary
objective was to assess the objective response rate. Secondary
objectives included the assessment of overall survival, pro-
gression-free survival (PFS), and assessing the qualitative
and quantitative toxicities of sorafenib in this patient cohort.
In addition, specimens were collected for the Lung
Cancer Specimen Repository Protocol (S9925) for analyses
of the relationship between selected markers and patient
outcomes. Analysis of tumor and serum for angiogenic mark-
ers is ongoing and will be reported separately.
All participating centers were required to have institu-
tional review board approval for the study, and all patients
gave written informed consent to participate in this study in
accordance with institutional and federal guidelines. This
study (Clinical Trials Registration Identification Number:
NCT00182689) was monitored by the Data and Safety Mon-
itoring Committee of the Southwest Oncology Group.
Eligibility Criteria
Eligible patients had histologically or cytologically
confirmed diagnosis of SCLC, with measurable disease per
RECIST criteria, Zubrod performance status of 0 to 1, with
adequate hematologic, hepatic, and renal function. Patients
must have received exactly one prior platinum-based regi-
men. Patients with asymptomatic, treated brain metastases
that did not require either enzyme-inducing anticonvulsants
or corticosteroid therapy to control symptoms were eligible.
Patients had to be able to tolerate oral medication. Women/
men of reproductive potential who entered the study agreed to
use an effective contraceptive method.
Treatment
Patients were treated with oral sorafenib 400 mg twice
daily for a 28-day cycle. This study used the National Cancer
Institute Common Terminology Criteria for Adverse Events
Version 3.0 for toxicity and adverse event reporting. Inter-
ruptions and delays of sorafenib therapy were allowed for up
to 3 weeks for grade 3 and grade 4 toxicities. Dose reduction
to 200 mg twice daily was allowed for subsequent cycles after
resolution of toxicity tograde 2. The second dose reduction
to 200 mg daily was allowed. If treatment delay exceeded 3
weeks for toxicity resolution or grade 3 or greater toxicities
were seen at the lowest dose reduction, the patient was
removed from protocol treatment.
Statistical Considerations
The primary endpoint was to evaluate the objective
response rate (confirmed and unconfirmed, complete, and
partial responses per RECIST). Confirmation of response
required that repeat studies be performed at least 4 weeks
after criteria for response were first met. Duration of response
was measured from the date that response criteria were first
met until the date of disease progression. Secondary end-
points included PFS and overall survival. Patients were strat-
ified into platinum-sensitive or platinum-refractory groups.
Platinum-sensitive disease was defined as an initial response
to platinum-based chemotherapy and progression 90 days
after the last platinum treatment; whereas platinum-refractory
disease was defined as no response to platinum-based che-
motherapy or progression during or 90 days after the last
platinum treatment.
Parallel patient enrollment was implemented for both
strata, and a two-stage design proceeded separately for
each stratum. Initially, 20 patients were to be accrued to
each stratum. If no responses were observed in the first 20
patients, then accrual was to be stopped in that stratum with
the conclusion that sorafenib was not promising in the group
of patients represented by that stratum. If one or more
responses were observed in the first 20, an additional 20
patients were to be accrued to the stratum. Five or more
responses of the total 40 patients in a stratum were considered
as evidence warranting further study of sorafenib in that
group of patients, providing other factors such as toxicity,
PFS, and overall survival, also appeared favorable. If four or
fewer responses in 40 patients were observed in a stratum,
further study of sorafenib would not be warranted in that
setting. In either stratum, the probability of falsely declaring
sorafenib as warranting further study was 0.05 (alpha) when
the true response rate was 5%; the probability of correctly
declaring sorafenib as warranting further study was 0.92
(power) when the true response rate was 20%. Within each
stratum, 40 patients would be sufficient to estimate the response
rate and the rates of individual toxicities to within 16% (95%
confidence interval), and any toxicity occurring with at least 5%
probability would have an 87% chance to be seen at least once.
Overall survival and PFS estimates were calculated
using the method of Kaplan and Meier,6 and 95% confidence
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intervals for their medians were constructed using the method
of Brookmeyer and Crowley.7 Exact binomial confidence
intervals were calculated for response outcomes.
RESULTS
The study met its accrual goal, and 89 patients were
registered between July 2005 and February 2007. In each
stratum, at least one objective response was documented
among the first 20 patients enrolled warranting that accrual
continued through the second stage. Five patients were inel-
igible, two because of inadequate hepatic function, one be-
cause of inadequate blood coagulation, and two because of no
evidence of measurable disease by RECIST criteria. One
eligible patient did not receive any protocol treatment be-
cause of early disease progression and was not analyzable for
any study endpoint. One additional eligible patient did not
have any adverse events assessed because of early death.
Patient characteristics are listed in Table 1. Median age
for the platinum-sensitive group was 65 versus 60 years in the
platinum-refractory group. Two thirds of patients in the
platinum-refractory group had multiple lesions in multiple
organs compared with approximately half of the patients in
the platinum-sensitive group. Approximately half of the pa-
tients in each group were current smokers.
The reasons for protocol discontinuation are summa-
rized in Table 2. The majority of patients (67%) were taken
off protocol for disease progression. An additional 19 patients
(23%) went off study because of adverse events or side
effects.
Efficacy
Tumor response is summarized in Table 3. There were
four partial responses seen among the 38 patients on the
platinum-sensitive stratum, for an estimated response rate of
11% (95% confidence interval: 3–25%), and one partial
response among the 45 patients in the platinum-refractory
stratum, for an estimated response rate of 2% (95% confi-
dence interval: 0–12%). Duration of the four responses seen
in the platinum-sensitive stratum was 9, 35, 57, and 274 days.
Duration of the single response in the platinum-refractory
stratum was 114 days.
The Kaplan-Meier estimates for PFS are presented in
Figure 1. The median PFS estimate for the platinum-refrac-
tory stratum was 2.0 months (95% confidence interval: 1.7–
2.2 months), and the estimated median PFS for the platinum-
sensitive stratum was 2.2 months (95% confidence interval:
1.8–3.2 months).
Overall survival is presented in Figure 2. The median
overall survival estimates were 5.3 months (95% confidence
interval: 3.3–7.5 months) and 6.7 months (95% confidence
interval: 6.1–9.1 months) for the platinum-refractory and
platinum-sensitive strata, respectively.
Toxicity
Eighty-two patients were assessed for adverse events
related to treatment. There was one treatment-related death
TABLE 2. Treatment Summary by Platinum Sensitivity
Reason of Treatment Total
Platinum
Sensitive
Platinum
Refractory
Adverse events or side effects 19 8 11
Refusal unrelated to adverse events 4 2 2
Progression/relapse 56 27 29
Death 1 1 0
Other—not protocol specified 3 0 3
TABLE 3. Response by Platinum Sensitivity
Platinum Sensitive
(%)
Platinum Refractory
(%)
Partial response 0 (0) 1 (2)
Unconfirmed partial response 4 (11) 0 (0)
Stable/no response 12 (32) 13 (29)
Progressive disease 17 (45) 19 (42)
Symptomatic deterioration 3 (8) 3 (7)
Assessment inadequate 2 (5) 9 (20)
Total 38 (100) 45 (100)
TABLE 1. Patient Characteristics by Platinum Sensitivity
Platinum Sensitive
(n  38)
Platinum Refractory
(n  45)
Age (yr)
Median (range) 65 (48–85) 60 (44–80)
Sex (%)
Males 20 (53) 27 (60)
Females 18 (47) 18 (40)
Race (%)
White 35 (92) 41 (91)
Black 1 (3) 1 (2)
Native American 1 (3) 2 (4)
Multiracial 1 (3) 0 (0)
Unknown 0 (0) 1 (2)
Sites of metastases (%)
Single organ 4 (11) 7 (16)
Multiple organs 32 (84) 34 (76)
None 1 (3) 3 (7)
Not reported 1 (3) 1 (2)
Performance status (%)
0 15 (39) 15 (33)
1 22 (58) 29 (64)
Not reported 1 (3) 1 (2)
Smoking history (%)
Current 17 (45) 25 (56)
Former 21 (55) 19 (42)
Never 0 (0) 0 (0)
Not reported 0 (0) 1 (2)
Weight loss prior 6 mo (%)
5% 26 (68) 31 (69)
5 to 10% 5 (13) 6 (13)
10 to 20% 1 (3) 5 (11)
20% 1 (3) 1 (2)
Not reported 5 (13) 2 (4)
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because of pancreatitis in the platinum-refractory stratum.
Two additional patients in the platinum-refractory stratum
experienced treatment-related grade 4 adverse events: one
because of elevated lipase and one because of nausea, vom-
iting, and dehydration. One patient in the platinum-sensitive
stratum experienced treatment-related grade 4 adverse events
including fatigue, dizziness, and dyspnea. The most common
treatment-related adverse events exceeding grade 2 were
dermatologic (22 patients, none grade 4) and constitutional
symptoms (nine patients, one grade 4). A summary of treat-
ment-related adverse events is given in Table 4.
DISCUSSION
In this multicenter cooperative group phase II clinical
trial, single-agent sorafenib induced an objective response in
five patients: one with platinum-refractory disease and four
with platinum-sensitive disease. The overall survival of 5.3
months (refractory/resistant) and 6.7 months (sensitive), and
the overall PFS of 2 months are similar to or inferior to
studies using chemotherapy in this setting. The survival
influence of subsequent lines of therapy was not tracked in
our trial and would be difficult to interpret in any event
because of the limited sample size. Clinical trials of topotecan
in sensitive relapsed SCLC have yielded time to progression
of approximately 3 months and median survival of 6 to 8
months.2,8,9 Topotecan in resistant/refractory disease has
yielded median survival of 5 to 6 months and time to
progression of about 3 months.3,10,11 Other cytotoxic agents
show promise for the treatment of relapsed SCLC, particu-
larly amrubicin, a fully synthetic anthracycline, which seems
to be active in both sensitive and resistant SCLC. Ongoing
phase III trials are evaluating this agent in either the first-line
setting of extensive stage or relapsed disease.12
The adverse events and toxicity profile noted in this
study are similar to other reported phase II clinical trials of
sorafenib. In our population of patients with SCLC, there were
no significant bleeding or thromboembolic events noted. The
23% of patients who were taken off study due to adverse events
are comparable with other clinical trials studying sorafenib in
patients with hepatocellular and thyroid carcinoma.13,14
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FIGURE 1. Progression-free survival
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stage small cell lung cancer treated
with sorafenib.
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The five objective responses seen in our trial serve as
evidence of therapeutic activity of tyrosine kinase inhibition
in SCLC in this small subset of patients. However, even for
those responding, this benefit was short lived. Clearly, the
majority of patients were quite resistant to sorafenib. We can
only speculate on the potential mechanisms of sensitivity and
resistance operative in these patients.
Sorafenib was initially identified as an inhibitor of Raf
serine/threonine kinase isoforms. At the initiation of this trial,
the frequency of activating oncogenic mutation of B-Raf in
SCLC was not characterized. In a recent study of 104 human
tumor cell lines, only 1 of 34 (2.9%) SCLC cell lines was found
to have the T1796A transversion, which confers constitutive
kinase activity.15 However, activation of Ras oncogene signaling
is considered an important mechanism by which human cancer
develops and through which the malignant phenotype is main-
tained. Raf kinase is involved in the Ras signal transduction
pathway regulating several key pathways inducing cellular
transformation, including the Raf/Mek/Erk cascade.16 In vivo
sorafenib demonstrated activity against several human tumor
xenografts both wild type and mutant for Kras.17
Sorafenib is currently Food and Drug Administration
approved for the treatment of advanced renal cell carcinoma
and unresectable hepatocellular carcinoma. Cellular signaling
mediated by VEGF pathways has been implicated in the
molecular pathogenesis of both hepatocellular carcinoma and
renal cell carcinoma,18,19 and inhibition of VEGFR-2 is felt to
be the primary mechanism of antitumor effect for sorafenib in
these malignancies. Functional VEFGR-2 and VEGFR-3
have been found in human SCLC cell lines.20 Clinical inves-
tigations have correlated elevated pretreatment serum levels
of VEGF and basic fibroblast growth factor to poor response
to chemotherapy and shortened survival in patients with
SCLC.21 In addition to direct inhibition of VEGFR-2, sor-
afenib may also exert antiangiogenic effects through inhibition
of Raf-1. Recent evidence suggests VEGF and/or basic fibro-
blast growth factor activation of Raf-1 results in protection from
distinct pathways of apoptosis in human endothelial cells.22
Based on the data discussed earlier in the text, includ-
ing the rarity of Raf mutations in SCLC and the activity of
sorafenib in renal cell carcinoma and hepatocellular cancer,
one might speculate the objective responses seen in our
SCLC population were due to antiangiogenic effects. Thalid-
omide, an agent with both immunomodulatory and antiangio-
genic properties, has been tested in SCLC. A phase III trial of
cisplatin plus etoposide with or without thalidomide in pa-
tients with limited or ES-SCLC failed to improve survival in
724 randomized patients.23 Clinical trials of tyrosine kinase
inhibitors targeting the VEGFR have been explored in SCLC.
Cediranib is a potent inhibitor of VEGFR-1, 2, and 3 tyrosine
kinases. A phase II study evaluated cediranib in patients with
progressive SCLC after one prior platinum-based regimen.24
Of 25 treated patients, there was one unconfirmed partial
response, and the trial was terminated for not meeting its
predefined efficacy goal. Serial plasma VEGF levels did not
correlate with anticancer effects in the small cohort of pa-
tients. A phase I trial to assess the safety and tolerability of
cediranib in combination with etoposide and cisplatin as
first-line therapy for SCLC has been completed and had
promising efficacy,25 and the Southwest Oncology Group is
planning a phase II/III trial of this combination. A random-
ized phase II study using vandetanib, a dual pathway inhibitor
of VEGFR and EGFR, as maintenance after objective re-
sponse to first-line platinum-based chemotherapy in SCLC,
showed no benefit in terms of overall survival or PFS, when
compared with placebo.26 A phase I/II trial combining
sunitinib with etoposide and cisplatin as first-line therapy for
ES-SCLC is ongoing by the Cancer and Leukemia Group B
(CALGB 30504 and NCT00453154).
Similarly, monoclonal antibodies targeting VEGF path-
ways have been explored in SCLC trials. Two phase II
studies of irinotecan plus platinum combined with bevaci-
zumab in untreated ES-SCLC suggested modest improve-
ments in response and survival relative to historical controls,
but they did not achieve the outcomes necessary to move on
to phase III trials.27,28
In related pathways, up to 70% of SCLC tumors also
express c-KIT and its ligand stem cell factor resulting in a
functional autocrine growth loop.20,29 Imatinib, an inhibitor of
the c-KIT tyrosine kinase enzyme, was evaluated in a phase II
clinical trial of patients with SCLC and either chemotherapy-
naive extensive-stage disease or sensitive relapse.30 There were
no objective responses noted in 19 patients. Tumor tissue sam-
ples from 4 of the 19 patients (21%) had the KIT receptor
(CD117). In two similar phase II trials, patients with progressive
SCLC with c-KIT positive tumors were treated with single-
agent imatinib. In one trial, no responses were seen in 12
patients, and all had progressed by 4 weeks.31 In the other, no
objective responses and no confirmed stable disease 6 weeks
were seen.32 When combined with irinotecan and cisplatin in
two phase I studies, imatinib was found to statistically decrease
irinotecan clearance.33 A high incidence of hematologic and
TABLE 4. Adverse Events by Platinum Sensitivity
Adverse Events
Grades
Platinum
Sensitive
(n  38)
Platinum
Refractory
(n  44)
2 3 4 5 2 3 4 5
Allergy/immunology 0 0 0 0 1 1 0 0
Blood/bone marrow 2 0 0 0 2 1 0 0
Cardiac general 3 3 0 0 3 0 0 0
Coagulation 0 1 0 0 0 1 0 0
Constitutional symptoms 12 4 1 0 15 5 0 0
Dermatology/skin 11 11 0 0 14 11 0 0
Gastrointestinal 17 2 0 0 16 3 1 0
Hepatobiliary/pancreas 0 0 0 0 0 0 0 1
Infection 1 1 0 0 1 1 0 0
Metabolic/laboratory 2 4 0 0 2 4 1 0
Musculoskeletal/soft tissue 1 0 0 0 2 1 0 0
Neurology 6 2 1 0 1 3 0 0
Pain 6 3 0 0 3 4 0 0
Pulmonary/upper respiratory 1 2 1 0 3 1 0 0
Maximum grade any adverse event 10 23 1 0 15 20 2 1
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gastrointestinal toxicity prohibited dose escalation. Although
five of six evaluable patients experienced a partial response, the
pharmacologic interaction and intolerance precluded fur-
ther development.
Based on the lack of disease control seen in our trial,
further investigation of single-agent sorafenib in the SCLC
population is not recommended. The clinical promise of
combining chemotherapy with targeted agents in SCLC in
some instances, however, has been tempered by safety and
pharmacokinetic concerns. Recently, a phase I trial combin-
ing sorafenib with topotecan was suspended due to excessive
grades 3 and 4 thrombocytopenia (D.R. Leach, personal
communication). However, a phase I/II trial combining sor-
afenib with cisplatin and etoposide in ES-SCLC is recruiting
(NCT00726986). The introduction of novel agents into clin-
ical trials in SCLC and other malignancies will continue to
pose many challenges, such as the ability to safely combine
with other drugs at active doses, defining therapeutic end-
points, and prediction of efficacy based on target expression.
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